# Jacobio Pharmaceuticals

Source: https://onco.cc/companies/jacobio-pharmaceuticals/  
OnCo record `jacobio-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Jacobio Pharmaceuticals is a Chinese developer in Beijing that sponsors 6 registered cancer trials of JAB-30355 and JAB-2485.

## Summary

Jacobio Pharmaceuticals appears on ClinicalTrials.gov as the industry sponsor of 6 interventional cancer trials (phase 1/2), testing JAB-30355, JAB-2485, JAB-23E73, JAB-8263 in solid tumors, er+ breast cancer, triple negative breast cancer, tnbc, arid1a gene mutation. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Jacobio Pharmaceuticals Co., Ltd.
- Tags: ctgov-sponsor; china; registry-only
- HQ: Beijing, China
- Type: biotech

## Sources

- ClinicalTrials.gov: trials sponsored by Jacobio Pharmaceuticals: https://clinicaltrials.gov/search?spons=Jacobio%20Pharmaceuticals

## Connected records

- trials: [A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors](https://onco.cc/trials/nct04686682/), [A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration](https://onco.cc/trials/nct06959615/), [JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration](https://onco.cc/trials/nct06973564/), [JAB-2485 Activity in Adult Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05490472/), [JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation](https://onco.cc/trials/nct06386146/), [Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations](https://onco.cc/trials/nct07640295/)

---
JSON: https://onco.cc/api/v1/entities/jacobio-pharmaceuticals.json